ABBV (AbbVie) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ABBV AbbVie Inc ABBV
76 GF Score
Price $263.96
GF Value $220.81
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is AbbVie Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


AbbVie  (NYSE:ABBV) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


AbbVie Cyclically Adjusted PS Ratio Related Terms


AbbVie Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for AbbVie's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie Cyclically Adjusted PS Ratio Chart

AbbVie Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.57 6.82 5.96 6.28 7.47

AbbVie Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.22 7.61 7.43 6.86 7.75

ABBV vs MRK, JNJ, AMGN: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - General subindustry, AbbVie's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbbVie Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AbbVie's Cyclically Adjusted PS Ratio falls into.


ABBV
76GF Score
AbbVie Inc ABBV
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbbVie Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

AbbVie's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, AbbVie's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=9.593/333.9520*333.9520
=9.593

Current CPI (Jun. 2026) = 333.9520.

AbbVie Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 3.922 241.428 5.425
201612 4.187 241.432 5.792
201703 4.079 243.801 5.587
201706 4.340 244.955 5.917
201709 4.364 246.819 5.905
201712 4.831 246.524 6.544
201803 4.971 249.554 6.652
201806 5.266 251.989 6.979
201809 5.436 252.439 7.191
201812 5.607 251.233 7.453
201903 5.278 254.202 6.934
201906 5.563 256.143 7.253
201909 5.717 256.759 7.436
201912 5.861 256.974 7.617
202003 5.808 258.115 7.514
202006 6.330 257.797 8.200
202009 7.273 260.280 9.332
202012 7.803 260.474 10.004
202103 7.330 264.877 9.242
202106 7.860 271.696 9.661
202109 8.071 274.310 9.826
202112 8.372 278.802 10.028
202203 7.614 287.504 8.844
202206 8.211 296.311 9.254
202209 8.340 296.808 9.384
202212 8.504 296.797 9.569
202303 6.883 301.836 7.615
202306 7.829 305.109 8.569
202309 7.864 307.789 8.532
202312 8.071 306.746 8.787
202403 6.943 312.332 7.424
202406 8.166 314.175 8.680
202409 8.160 315.301 8.643
202412 8.537 315.605 9.033
202503 7.530 319.799 7.863
202506 8.709 322.561 9.017
202509 8.903 324.800 9.154
202512 9.368 324.054 9.654
202603 8.457 330.213 8.553
202606 9.593 333.952 9.593

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is AbbVie (ABBV) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of $263.96 is trading 19.5% above its estimated GF Value™ of $220.81. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for ABBV:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $220.81 vs. price of $263.96 (19.5% above fair value)
  • GF Score™: 76/100 with 5 warning signs

No single metric tells the full story. See the ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
76GF Score

Get the complete analysis for ABBV

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$263.96
Price
$220.81
GF Value